Pharma & LIFE SCIENCES
Defensible governance for pharma and life sciences
Pharma and life sciences companies are held to the highest standards in clinical and product compliance. Datamaran brings that same rigor to governance, giving you the real-time intelligence you need to mitigate risk and make decisions you can stand behind.
Trusted by leading companies worldwide
Industry challenges
Why pharma & life science companies face intense regulatory and reputational pressure
Across pharma, biotech, and medtech, companies face the same pressures: regulation that moves faster than internal tracking, governance performance that investors and regulators now scrutinize as closely as financial results, and risk data too fragmented to defend under that scrutiny
Complex Regulatory Landscape
From drug pricing and tariffs to device regulation and wastewater rules, requirements are shifting across markets at the same time. Without continuous tracking, pharma, biotech, and medtech companies risk finding compliance gaps only after they’ve become costly.
Reputational and Investor Scrutiny
Investors, regulators, and patients increasingly judge life sciences companies on how they manage issues like access to medicines, product safety, and supply chain ethics. Gaps in disclosure or governance can quickly become financial and reputational risk.
Fragmented Risk Data
External risk data is often spread across regulatory affairs, quality, R&D, and sustainability teams, making it hard to build a coherent, audit-ready view that satisfies both leadership and external stakeholders.
Solution
A clear view of the global emerging risk landscape
Datamaran helps pharma and life science companies identify priority issues, stay ahead of regulatory change, benchmark strategy, and build defensible disclosures. With AI-powered analytics, risk intelligence, and cross-functional workflows, that deliver a structured approach that strengthens governance and decision-making.
Regulatory Monitoring
Identify compliance risks before they impact your business
Track regulatory changes across 190+ countries
Monitor pharma- and device-specific mandates, from drug pricing rules to the EU MDR, alongside cross-sector requirements like CSRD, in real time to prevent compliance gaps.
Understand governance issues across R&D and manufacturing
Stay on top of emerging regulations affecting patient safety, product stewardship, supply chain ethics, and workforce standards before they become problems.
Build audit-ready regulatory governance
Ensure every regulatory signal is logged, tracked, and managed, and is ready for board or assurance review.
Core
Continuous visibility of material risks across your portfolio
Quantify regulatory and reputational risks
Connect compliance mandates, patient safety, and workforce governance directly to your materiality assessment and overall risk picture.
Automate issue prioritization for complex operations
Run evidence-based assessments across global operations without the need for manual spreadsheets or consultants.
Align external risks with enterprise risk registers
Give your colleagues and C-suite a traceable, audit-ready view of what's material across your full value chain.
Suite
Benchmark priorities against pharma & life science peers
Compare risks against leading pharma and medtech companies
See how peers across drugs and devices are disclosing on patient access, product safety, supply chain resilience, and environmental impact.
Pinpoint reporting gaps before external auditors do
Identify where your disclosures fall short of sector norms and regulatory expectations.
Set credible targets based on industry evidence
Ground climate and governance targets in what leading industry peers are actually committing to.
Customer spotlight
How Organon built a data-backed strategy
With increasing scrutiny from investors, regulators, and consumers on ESG topics, Organon needed to develop an ESG strategy fast. Using Datamaran, it carried out a materiality analysis to identify priority risks and issues, and now relies on the platform for always-on intelligence that supports executive decisions.
140
Markets covered by the materiality assessment
10-K
Insights used to support Organon's filings
Why pharma & life science companies choose Datamaran
Continuous risk monitoring
Replace periodic reviews with always-on intelligence across 190+ countries.
Defensible data trails
Every materiality decision is traceable, documented, and audit-ready.
Colleague and C-suite alignment
Surface priorities as structured risk intelligence for leadership and board teams.
Scalable across operations
From a single market to a global portfolio, Datamaran scales with your business.
